Can you take Aerius with Asparaginase erwinia chrysanthemi?

The desloratadine in Aerius has a moderate potential interaction with Asthma.

Desloratadine products contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. Caution is advised when using these products in people with asthma.

asparaginase Erwinia chrysanthemi has a major potential interaction with Bleeding Disorder.

Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with the use of Erwinia-derived L-asparaginase therapy. Its use is contraindicated in patients with history of serious thrombosis or hemorrhagic events with prior L-asparaginase therapy. It is recommended to exercise caution in patients predisposed to thrombotic or hemorrhagic events. It is recommended to discontinue asparaginase Erwinia chrysanthemi if thrombotic or hemorrhagic event occur until symptoms resolve.

asparaginase Erwinia chrysanthemi has a moderate potential interaction with Diabetes Mellitus.

The use of asparaginase Erwinia chrysanthemi has been associated with glucose intolerance. Exercise caution when using this agent in patients with diabetes. It is recommended to monitor glucose levels at the start of therapy, and periodically thereafter in all patients. Administer insulin therapy as necessary in patients with hyperglycemia.

The desloratadine in Aerius has a moderate potential interaction with Liver Disease.

Dosing adjustment of desloratadine is recommended for patients with renal or hepatic impairment. Dosing recommendations for children with liver or renal impairment cannot be made due to lack of data.

asparaginase Erwinia chrysanthemi has a major potential interaction with Pancreatitis.

The use of asparaginase Erwinia chrysanthemi is contraindicated in patients with a history of serious pancreatitis with prior L-asparaginase therapy. It is recommended to evaluate patients with symptoms compatible with pancreatitis to establish a diagnosis. In the case of mild pancreatitis, it is recommended to hold treatment until the signs and symptoms subside, and amylase levels return to normal. Discontinue treatment with this agent for severe or hemorrhagic pancreatitis manifested by abdominal pain >72 hours and amylase elevation of >= 2.0 x ULN.

The desloratadine in Aerius has a moderate potential interaction with Renal Dysfunction.

Dosing adjustment of desloratadine is recommended for patients with renal or hepatic impairment. Dosing recommendations for children with liver or renal impairment cannot be made due to lack of data.

asparaginase Erwinia chrysanthemi has a major potential interaction with Thrombotic/Thromboembolic Disorder.

Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with the use of Erwinia-derived L-asparaginase therapy. Its use is contraindicated in patients with history of serious thrombosis or hemorrhagic events with prior L-asparaginase therapy. It is recommended to exercise caution in patients predisposed to thrombotic or hemorrhagic events. It is recommended to discontinue asparaginase Erwinia chrysanthemi if thrombotic or hemorrhagic event occur until symptoms resolve.